REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsNov 14 (Reuters) - The U.S. Food and Drug Administration said on Tuesday it had sent a warning letter to Amazon.com (AMZN.O) related to sale of seven unapproved eye drops on the company's e-commerce platform.
In the letter dated Nov. 13, FDA said Amazon was selling eye drops which have not been recognized as safe and effective for providing temporary relief from eye symptoms such as excessive watery discharge, redness, burning, or pink eye.
Eye products generally pose a greater risk of harm to consumers as they bypass some of the body's natural defenses, the agency said.
The seven products flagged in the letter to Amazon include Similasan Pink Eye Relief, Can-C Eye Drops, Optique 1 Eye Drops, OcluMed Eye Drops, among others.
In September, FDA warned eight companies, including pharmacy giants CVS Health (CVS.N) and Walgreens Boots Alliance (WBA.O), against manufacturing or marketing of certain unapproved eye products.
Persons:
Brendan McDermid, Privately, Similasan, Bhanvi, Shounak Dasgupta
Organizations:
Amazon, REUTERS, U.S . Food, Drug Administration, FDA, Eye, CVS Health, Walgreens Boots Alliance, Thomson
Locations:
New York City, U.S, Bengaluru